Literature DB >> 20616683

Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.

Daphna Mezad-Koursh1, Michaella Goldstein, Gad Heilwail, Shiri Zayit-Soudry, Anat Loewenstein, Adiel Barak.   

Abstract

PURPOSE: The purpose of this study was to describe the clinical characteristics and management of patients with bacterial endophthalmitis after an intravitreal antivascular endothelial growth factor injection.
METHODS: This is a retrospective chart review of all patients admitted with suspected endophthalmitis from 2006 to 2008.
RESULTS: Endophthalmitis was verified by positive Gram stain and culture in nine eyes. The mean preinjection visual acuity of the 9 eyes was 0.02 +/- 0.021 diopters (decimal visual acuity scale) and dropped to 0.01667 +/- 0.02449 diopters in the eyes with endophthalmitis. All nine patients presented with reduced visual acuity, of whom seven also had ocular pain. Initial treatment was administered without delay and consisted of vitreous tap and intravitreal antibiotics injection in five cases and pars plana vitrectomy with intravitreal antibiotics injection in the other four cases. Vitreous tap failed in one case. Seven patients underwent a second procedure and two underwent a third procedure. The mean posttreatment visual acuity in all 9 eyes improved significantly (0.19 +/- 0.24, P = 0.0071). Five patients had major complications (e.g., retinal detachment, phacolytic glaucoma, and recurrent endophthalmitis).
CONCLUSION: Acute endophthalmitis following anti-VEGF injection appears within days and can result in severe loss of vision if not treated promptly. In our series the clinical and prognostic characteristics were considerably different between culture positive endophthalmitis cases and culture negative cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616683     DOI: 10.1097/IAE.0b013e3181cd47ed

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Endophthalmitis following intravitreal injections.

Authors:  Cristina Irigoyen; Kimia Ziahosseini; George Morphis; Theodor Stappler; Heinrich Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-03       Impact factor: 3.117

Review 2.  Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration.

Authors:  Yasha S Modi; Carley Tanchon; Justis P Ehlers
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

Review 3.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Authors:  K Ghasemi Falavarjani; Q D Nguyen
Journal:  Eye (Lond)       Date:  2013-05-31       Impact factor: 3.775

4.  A Large Outbreak of Fulminant Bacterial Endophthalmitis after Intravitreal Injection of Counterfeit Bevacizumab.

Authors:  Morteza Entezari; Saeed Karimi; Hamid Ahmadieh; Amir Hossein Mahmoudi; Hamid Parhizgar; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-04       Impact factor: 3.117

5.  Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center".

Authors:  Inci Elif Erbahçeci; Kemal Ornek
Journal:  Retina       Date:  2012-06       Impact factor: 3.975

Review 6.  Endophthalmitis: state of the art.

Authors:  Kamyar Vaziri; Stephen G Schwartz; Krishna Kishor; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-01-08

7.  Bevasiranib for the treatment of wet, age-related macular degeneration.

Authors:  Adinoyi O Garba; Shaker A Mousa
Journal:  Ophthalmol Eye Dis       Date:  2010-12-19

Review 8.  Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.

Authors:  Rupali Singh; Samaneh Davoudi; Steven Ness
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-12       Impact factor: 3.535

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.